(S1 (S (S (NP (NP (JJ Postoperative) (NN progression)) (PP (IN of) (NP (JJ pulmonary) (NN metastasis))) (PP (IN in) (NP (NN osteosarcoma))))) (. .)))
(S1 (S (S (NP (NP (JJ Early) (NN relapse)) (PP (IN with) (NP (JJ distant) (NN metastasis)))) (ADVP (RB often)) (VP (VBZ is) (VP (VBN observed) (PP (IN in) (NP (NP (NNS patients)) (PP (IN with) (NP (NN cancer))))) (PP (IN after) (NP (NP (NN resection)) (PP (IN of) (NP (DT the) (JJ primary) (NN tumor)))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (VP (VBN considered) (SBAR (IN that) (S (NP (NP (NN resection)) (PP (IN of) (NP (DT the) (JJ primary) (NN tumor)))) (VP (VP (VBZ induces) (NP (NP (NN activation)) (PP (IN of) (NP (JJ systemic) (NN angiogenesis))))) (CC and) (VP (VBZ enhances) (NP (NP (NN progression)) (PP (IN of) (NP (JJ remote) (NN metastasis))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NNS authors)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (NN resection)) (PP (IN of) (NP (DT the) (JJ primary) (NN osteosarcoma) (NN tumor)))) (VP (VBZ enhances) (NP (NP (NN progression)) (PP (IN of) (NP (JJ pulmonary) (NN metastasis))) (PP (IN in) (NP (NN animal) (NN osteosarcoma) (NNS models))))))))) (. .)))
(S1 (S (S (NP (NN Matrigel) (NN plug) (NN neovascularization) (NN assay)) (VP (VBD revealed) (SBAR (IN that) (S (NP (JJ systemic) (JJ angiogenic) (NN activity)) (VP (VBD was) (VP (VBN elevated) (PP (IN after) (NP (NP (JJ primary) (NN tumor) (NN removal)) (PRN (-LRB- -LRB-) (NP (NP (NN tumor) (JJ intact) (NN group)) (, ,) (NP (QP (CD 1.61) (CC +/-) (CD 0.21)) (NN g/dL)) (: ;) (NP (ADJP (NN tumor) (VBN removed)) (NN group)) (, ,) (NP (QP (CD 4.92) (CC +/-) (CD 0.35)) (NN g/dL))) (-RRB- -RRB-)))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (NN serum) (NN concentration)) (PP (IN of) (NP (NP (DT the) (NN angiogenesis) (NN inhibitor)) (, ,) (NP (NN endostatin)) (, ,)))) (VP (VBD decreased) (ADVP (RB significantly)) (PP (IN after) (NP (JJ primary) (NN tumor) (NN removal))))) (. .)))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (DT the) (JJ antiangiogenic) (NN reagent) (NN TNP-470)))) (VP (VBD suppressed) (NP (NP (JJ postoperative) (NN progression)) (PP (IN of) (NP (JJ pulmonary) (NN metastasis)))))) (. .)))
(S1 (S (S (NP (DT These) (NNS results)) (VP (VBP indicate) (NP (DT the) (NN possibility) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (JJ angiogenic) (NN activity))) (PP (IN after) (NP (NP (NN resection)) (PP (IN of) (NP (NN osteosarcoma) (NNS tumors)))))) (VP (VBZ enhances) (NP (NP (NN progression)) (PP (IN of) (NP (JJ pulmonary) (NN metastasis)))))))))) (. .)))
(S1 (S (S (NP (DT The) (JJ current) (NNS data)) (ADVP (RB also)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN administration)) (PP (IN of) (NP (JJ antiangiogenic) (NNS reagents)))) (VP (MD can) (VP (VB prevent) (NP (NP (NN progression)) (PP (IN of) (NP (JJ pulmonary) (NN metastasis))) (PP (IN in) (NP (NN osteosarcoma)))) (ADVP (RB postoperatively)))))))) (. .)))
